Only the combinations of the dominant strategies (more effective and less costly) were reported.
In patients with no CAD, and assuming that TCAs increase mortality, the most cost-effective strategy was gabapentin, TCA, pregabalin, opioid and tramadol, with an incremental cost-effectiveness ratio (ICER) of $8,300.
For patients without CAD, and assuming that TCAs increase mortality, the most cost-effective strategy was TCA, gabapentin, pregabalin, opioid and tramadol, with an ICER of $15,600.
For patient with CAD, the most cost-effective strategy was gabapentin, pregabalin, opioid and tramadol, with an ICER of $15,600.
The results of the sensitivity analysis showed the likelihood that a given medication would be first, second, or third in a sequential medication strategy considered acceptable from a societal standpoint for a series of willingness-to-pay thresholds. However, given the extensive level of reporting, the reader of this abstract is referred to the full paper for further details.